Over Half of Cardiology Patients May Qualify for Semaglutide Under New Guidelines
Real-world registry data shows 54% of coronary artery disease patients meet eligibility criteria for semaglutide based on SELECT and SOUL trial standards.
Summary
Two landmark trials — SELECT and SOUL — proved that semaglutide, the GLP-1 receptor agonist behind Ozempic and Wegovy, reduces heart attacks and cardiovascular death in patients with coronary artery disease, with or without diabetes. But how many real-world patients actually qualify? Italian researchers analyzed nearly 12,000 cardiology patients from two national registries and found that more than half — about 54% — meet the regulatory eligibility criteria. Among non-diabetic patients, 42.5% qualified as overweight or obese with established coronary disease. Among diabetic patients, nearly 98% qualified. These findings suggest semaglutide could be a major tool in secondary cardiovascular prevention, and they highlight the need for healthcare systems to plan for the clinical and economic implications of widespread adoption.
Detailed Summary
Semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes, has emerged as a powerful cardiovascular drug following the SELECT and SOUL trials. SELECT demonstrated cardiovascular benefit in overweight or obese patients without diabetes, while SOUL extended that benefit to patients with diabetes aged 50 and older. Together, these trials prompted regulatory agencies to expand semaglutide's approved indications to include cardiovascular risk reduction in atherosclerotic disease. The critical question now is: how many real-world patients actually qualify?
To answer this, Italian cardiologists drew from two national prevention registries — START and BRING-UP — comprising 12,430 patients with chronic coronary artery disease. After excluding those with severe renal impairment or who were already on GLP-1 therapy, the final cohort included 11,807 patients. Researchers then mapped each patient to eligibility criteria derived from the SELECT and SOUL trials as defined by regulatory authorities.
The results were striking. Among 8,682 non-diabetic patients, 42.5% met SELECT-like criteria — meaning they were overweight or obese with established coronary disease. Among 3,125 diabetic patients, a remarkable 97.9% met SOUL-like criteria. In total, 6,748 patients — 54.3% of the full registry — were theoretically eligible for semaglutide under current regulatory guidance.
These numbers carry major implications for cardiology practice. Secondary cardiovascular prevention has traditionally relied on statins, antiplatelets, and blood pressure medications. Adding semaglutide to this armamentarium for more than half of patients represents a fundamental shift in treatment strategy, one with profound resource and prescribing implications.
Several caveats apply. Registry patients may differ in important unmeasured ways from trial participants. Real-world prescribing will also be shaped by cost, access, tolerability, and patient preference. Nonetheless, this analysis provides a valuable population-level estimate that can guide healthcare planning and identify where the greatest unmet need lies.
Key Findings
- 54.3% of real-world coronary artery disease patients meet regulatory eligibility criteria for semaglutide.
- 42.5% of non-diabetic coronary patients qualify based on SELECT trial criteria (overweight/obese with coronary disease).
- 97.9% of diabetic coronary patients aged 50+ qualify based on SOUL trial criteria.
- Over 6,700 of nearly 12,000 registry patients are theoretically eligible for semaglutide therapy.
- Findings highlight major unmet need and resource-planning challenges for cardiovascular prevention programs.
Methodology
Researchers cross-referenced 12,430 patients from two Italian national cardiology registries (START and BRING-UP) against eligibility criteria from the SELECT and SOUL randomized trials. Patients with severe renal impairment or existing GLP-1 therapy were excluded, leaving 11,807 for analysis. This is a retrospective observational analysis, not a prospective study or intervention trial.
Study Limitations
Summary is based on the abstract only; full methodology and subgroup data were not available for review. Registry populations may differ from trial cohorts in unmeasured ways, potentially affecting real-world applicability. Theoretical eligibility does not account for patient preference, tolerability, cost barriers, or contraindications beyond renal impairment.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: